Cargando…

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A

BACKGROUND: Data on the effect of ABO blood group (ABO), von Willebrand factor (VWF) levels, and age on factor VIII (FVIII) in non‐severe haemophilia A (HA) is scarce. OBJECTIVE: To investigate if ABO, VWF levels, and age have an influence on the variability of FVIII levels and consequently on the a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rejtő, Judit, Königsbrügge, Oliver, Grilz, Ella, Hofer, Stefanie, Mauracher, Lisa‐Marie, Gabler, Cornelia, Schuster, Gerhard, Feistritzer, Clemens, Sunder‐Plaßmann, Raute, Quehenberger, Peter, Gebhart, Johanna, Ay, Cihan, Pabinger, Ingrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	HAEMOSTASIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318586/ https://www.ncbi.nlm.nih.gov/pubmed/32073230 http://dx.doi.org/10.1111/jth.14770

Ejemplares similares

Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status
por: Rejtő, Judit, et al.
Publicado: (2023)

Thrombin‐generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause
por: Hofer, Stefanie, et al.
Publicado: (2019)

Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study
por: Goudemand, Jenny, et al.
Publicado: (2020)

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII
por: Hu, Yong, et al.
Publicado: (2022)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
por: Pagliari, Maria Teresa, et al.
Publicado: (2022)

Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding
por: Atiq, Ferdows, et al.
Publicado: (2021)

The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms
por: Sacco, Monica, et al.
Publicado: (2022)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

P1663: THE EFFECTS OF OBESITY ON BLEEDING FREQUENCY AND PARAMETERS OF FIBRINOLYSIS IN PATIENTS WITH NON-SEVERE HEMOPHILIA
por: Königsbrügge, O., et al.
Publicado: (2022)

Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach
por: Winterling, Karina, et al.
Publicado: (2021)

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts
por: Chun, Haarin, et al.
Publicado: (2022)

Von Willebrand disease type 2M: Correlation between genotype and phenotype
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2021)

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age‐related increase of VWF in von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018)

Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
por: Ay, Cihan, et al.
Publicado: (2021)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2018)

Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device‐induced acquired von Willebrand syndrome
por: Deconinck, Shannen, et al.
Publicado: (2018)

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022)

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery
por: Peyvandi, F., et al.
Publicado: (2018)

Evaluation of a semi‐automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers
por: Bowyer, Annette E., et al.
Publicado: (2018)

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
por: Bar Barroeta, Awital, et al.
Publicado: (2019)

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
por: Testa, Sophie, et al.
Publicado: (2019)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa
por: Yi, B. Alexander, et al.
Publicado: (2021)

Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua
por: Robinson, Mary M., et al.
Publicado: (2021)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Von Willebrand factor multimer quantitation for assessment of cardiac lesion severity and bleeding risk
por: Austin, Christopher O., et al.
Publicado: (2017)

Comparative sequence analysis of vitamin K‐dependent coagulation factors
por: Stojanovski, Bosko M., et al.
Publicado: (2022)

Probing activation‐driven changes in coagulation factor IX by mass spectrometry
por: Freato, Nadia, et al.
Publicado: (2021)

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study
por: Obermeier, Hanna L., et al.
Publicado: (2019)

Evaluation of von Willebrand factor concentrates by platelet adhesion to collagen using an in vitro flow assay
por: Riddell, Anne, et al.
Publicado: (2018)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021)

Characterization of laboratory coagulation parameters and risk factors for intraventricular hemorrhage in extremely premature neonates
por: Roberts, Jonathan C., et al.
Publicado: (2022)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes
por: Branchini, Alessio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tp1kcbfvjd92gsski380qmps7i